Product Detailed Description

liposomal S-Acetyl-L-Glutathione 70% — High Bioavailability Intracellular Glutathione Precursor Supplement

Product Overview

Liposomal S-Acetyl-L-Glutathione 70% is a premium-grade dietary supplement ingredient delivering S-acetyl-L-glutathione in an advanced liposomal delivery system. S-Acetyl-L-glutathione (CAS 3054-47-5), also known as S-acetylglutathione or SAG, is an acetylated tripeptide composed of cysteine, glutamic acid, and glycine, with the molecular formula C₁₂H₁₉N₃O₇S and a molecular weight of 349.36 g/mol. The compound is an S-acylglutathione in which the S-acyl group is specified as acetyl, and it has demonstrated roles as an anti-HSV-1 agent and apoptosis inducer. SAG is chemically synthesized through an S-acetylation reaction of L-GSH, and the obtained acetylated product is purified before being packaged.

Glutathione (GSH) is a tripeptide comprised of three amino acids (cysteine, glutamic acid, and glycine) present in most mammalian tissue, and is the most abundant nonprotein thiol that defends against oxidative stress in mammals. However, native GSH is not well absorbed from the gut, has a short half-life in blood plasma, and is not efficiently taken up by cells. SAG addresses these limitations through chemical S-acetylation of the thiol group on the cysteinyl amino acid of GSH, and oral administration of SAG has been shown to be more effective in restoring intracellular glutathione levels compared to oral glutathione.

Why Liposomal Technology?

Conventional SAG, while already offering superior stability and bioavailability compared to native GSH, can be further enhanced through liposomal encapsulation. Liposomal delivery systems provide an additional protective layer that shields SAG during digestive transit and facilitates efficient cellular delivery.

Liposomal encapsulation provides four critical advantages:

1. Enhanced Stability and Cellular Retention — SAG is stable in blood and can be converted to glutathione by intracellular thioesterases. Liposomal encapsulation provides an additional protective barrier, ensuring that more intact SAG reaches the systemic circulation and target cells. SAG is more stable than GSH, and liposomal encapsulation further extends its stability profile.

2. Direct Intracellular Delivery — SAG enables direct intracellular delivery of the active glutathione molecule, providing enhanced bioavailability. Unlike GSH, which is not well absorbed from the gut and has a short half-life in blood plasma, SAG is stable in plasma and can be taken up by cells directly.

3. Biomimetic Absorption Mechanism — Liposomal SAG utilizes a biomimetic delivery mechanism that bypasses the enzymatic degradation pathways responsible for the poor oral bioavailability of native GSH. The acetyl group on the sulfur atom enhances stability and bioavailability, making SAG a subject of interest in pharmaceutical and nutraceutical research.

4. Sustained Release for Prolonged Antioxidant Activity — Liposomal delivery provides a sustained-release profile that maintains steady plasma levels of SAG, supporting prolonged intracellular GSH restoration and antioxidant activity.

Product Specifications

Key Features

• High Purity — Standardized to ≥70% S-Acetyl-L-Glutathione by HPLC, with ≥97% assay available in compliance with EFSA novel food specifications.

• Liposomal Enhancement — Phospholipid bilayer encapsulation provides an additional protective layer, shielding SAG from premature degradation and enhancing cellular delivery.

• Superior Bioavailability — SAG avoids enzymatic degradation, exhibits a longer half-life, and is more efficiently absorbed and utilized compared to oral reduced glutathione.

• Direct Intracellular Delivery — SAG enables the direct intracellular delivery of the active glutathione molecule, providing enhanced bioavailability.

• Clinically Studied for Performance Recovery — Clinical trials are evaluating SAG at 200 mg and 500 mg daily in soccer players for performance recovery.

• Safety Validated — A 13-week repeated dose toxicity study in rats established a NOAEL of 1500 mg/kg/day, the highest dose tested, with no treatment-related adverse findings. Genotoxicity assays (Ames and micronucleus) were negative, and acute oral LD50 exceeded 2000 mg/kg.

• Skin Brightening and Anti-Aging — As a tyrosinase inhibitor, SAG reduces melanin production in cells caused by tyrosinase activity due to sun exposure, thereby achieving a whitening effect. It also reduces oxidative stress and inflammatory responses, helping to delay the skin aging process.

• Water-Dispersible — Liposomal powder offers excellent dispersibility in aqueous systems; suitable for capsules, tablets, powder drink mixes, and functional beverages.

• Batch Traceability — Complete COA, HPLC chromatogram, and identity data provided for each batch.

Application & Formulation Guidance

Recommended Dosage

The EFSA Panel on Nutrition, Novel Foods and Food Allergens has established a maximum safe intake level of 300 mg/day for adults, excluding pregnant and lactating women. For young adolescents (10 to <14 years) and older adolescents (14 to <18 years), the Panel considers SAG safe at intake levels up to 190 and 269 mg/day, respectively. Clinical trials in soccer players are evaluating daily doses of 200 mg and 500 mg for performance recovery. Commercial products typically provide 100–150 mg of SAG per capsule, with suggested use of 1–2 capsules daily. For general antioxidant and detoxification support, 100–300 mg daily is commonly used. Liposomal formulations may allow for more efficient utilization of lower doses due to enhanced bioavailability.

Shipping & Lead Time

• Stock Orders: 3–5 business days after payment confirmation.

• Bulk / Custom Orders: 2–3 weeks, depending on quantity and customization requirements.

• Shipping Methods: International Express (FedEx, DHL, UPS), air freight, and sea freight.

• Coverage: Worldwide shipping, including remote areas.